Back to News
Market Impact: 0.2
Biofrontera Submits Ameluz SNDA For Expanded Actinic Keratosis Use
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Biofrontera Inc. (BFRI) submitted a supplemental New Drug Application to the U.S. FDA seeking to expand the approved use of Ameluz with photodynamic therapy for actinic keratoses. The article reports the application submission, not an FDA decision.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
BFRI0.45
More News
- AI's Supercharging a Scam Economy Bigger Than the Cocaine Trade
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- ‘Piece by piece’: Trump administration vows to dismantle the International Criminal Court with sweeping new sanctions
- ‘Indentured servants’: US green card move will hit thousands of IT workers
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Research Tools for Pension Funds and Allocators
- AllMind's Data Standardization Methodology: Our Approach to Fundamentals